(Q34420891)

2 August 2017

title

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus (English)

1 reference

2 August 2017

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Nicola Coppola

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Antonio Riccardo Buonomo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Emanuela Zappulo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Guglielmo Borgia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Antonio Riccardo Buonomo

3

1 reference

2 August 2017

Emanuela Zappulo

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

21 May 2014

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1211-1223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Natural history of acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Evolving epidemiology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Hepatitis C: the clinical spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Influence of chronic coinfection with hepatitis B and C virus on liver histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Association of tattooing and hepatitis C virus infection: a multicenter case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Surrogate endpoints and non-inferiority trials in chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Perspectives and challenges of interferon-free therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Unravelling hepatitis C virus replication from genome to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Specifically targeted antiviral therapy for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Anti-HCV drugs in the pipeline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

New NS5B polymerase inhibitors for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

All-oral HCV therapies near approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Hepatitis C therapy with HCV NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Novel therapeutic approaches for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Meeting report: 26th International Conference on Antiviral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

TIMP-1 deficiency leads to lethal partial hepatic ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.921680

10.1517/13543784.2014.921680

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24848437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference